Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study

Initial Experience of Clinical Use of [<sup>99m</sup>Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study

Numerous different molecules of prostate-specific membrane antigen (PSMA) ligands are used to detect prostate cancer (PCa); most approaches utilize gallium PET and a few reports describe the role of SPECT/CT. [<sup>99m</sup>Tc]Tc-PSMA-T4 is a new radiopharmaceutical designed for the diag...

Full description

Bibliographic Details
Main Authors: Jarosław B. Ćwikła, Marek Roslan, Iwona Skoneczna, Monika Kempińska-Wróbel, Michał Maurin, Wojciech Rogowski, Barbara Janota, Anna Szarowicz, Piotr Garnuszek
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Series:Pharmaceuticals
Subjects:
prostate cancer
molecular imaging
prostate specific membrane antigen (PSMA)
[<sup>99m</sup>Tc]Tc-PSMA-T4
Online Access:https://www.mdpi.com/1424-8247/14/11/1107

Internet

https://www.mdpi.com/1424-8247/14/11/1107

Similar Items